In This Issue
Cancer Discov December 1 2017 7 (12) 1355-1357; DOI:10.1158/2159-8290.CD-ITI7-12
ctDNA profiling of pre- and post-treatment samples from patients with localized lung cancer identifies the presence of minimal residual disease earlier than standard imaging.
Endothelial activation and vascular disruption were associated with a high risk of severe neurotoxicity in 133 patients with B-cell malignancies treated with CD19-targeted CAR-T cell therapy.
Analysis of immune checkpoint inhibitor–resistant lung tumors revealed that loss of B2M expression may impair antigen processing to promote acquired resistance in patients with lung cancer.
Mutations that result in loss of primary cilia promote resistance to SMO inhibitors by eliminating formation of the GLI2 repressor form, allowing persistent low-level activation of hedgehog signaling.
Combined treatment with mTOR and HDAC inhibitors cooperatively suppresses thioredoxin to trigger excessive oxidative stress and induce cell death in NF1- and KRAS-mutant tumors
Inhibiting galectin-3 disrupts its interaction with integrin αvβ3, preventing the association with mutant KRAS to reduce macropinocytosis, increase ROS, and suppress KRAS-mutant tumor growth and progression.